Study Begins for Enopace's Catheter-Based Harmony Neuromodulation Device for Chronic Heart Failure

November 5, 2015—Enopace Biomedical, an Israel-based developer of minimally invasive, implantable endovascular neuromodulation therapy for heart failure patients, announced the first successful human implantation of its Harmony system. The catheter-based Harmony neurostimulator is intended for the treatment of patients with congestive heart failure.

Prof. Davor Milicic, MD, led a team that performed the procedure on a New York Heart Association class III heart failure patient. The clinical study, which will support the company’s application for CE Mark approval, is enrolling patients at several leading hospitals in Europe.

“We welcomed this great opportunity to work with the Enopace team in order to provide this breakthrough, innovative, minimally invasive treatment for chronic heart failure patients,” commented Prof. Milicic in the company’s press release. Prof Milicic is Head of Cardiology at Zagreb Medical University in Zagreb, Croatia.

According to Enopace, its leadless, implantable, catheter-based neurostimulator for heart failure patients increases cardiac efficiency by reducing left ventricular workload. The neuromodulation device operates inside a blood vessel and modulates the autonomic balance of heart failure patients using the leadless, active miniature stimulator. The device is implanted in a 30-minute percutaneous procedure.